



## IBA Notice of First Half Results and Conference Call

Louvain-la-Neuve, Belgium, August 14 August, 2013 - IBA ([Ion Beam Applications S.A.](http://www.ion-beam-applications.com)), the world's leading provider of proton therapy solutions for the treatment of cancer, will publish its consolidated results for the first half of 2013 on Thursday, 29 August 2013 at 07.00 CET.

In addition to the press release, Olivier Legrain, Chief Executive Officer, and Jean-Marc Bothy, Chief Financial Officer, will host a conference call and webcast to present the first half results, followed by a Q&A session.

This conference will be held on 29 August 2013 at 14:00 CET / 13:00 BST / 08.00 EDT and may be accessed on the home page of IBA website at <http://group.iba-worldwide.com/investor-relations>. If you want to take part in the Q&A, please dial the numbers that can be found in the half year results press release.

Shortly after the call, the presentation used in connection with the conference call webcast will be available on the IBA website. To ensure a timely connection, it is recommended that users register at least 10 minutes prior to the scheduled webcast.

###

### **For Further information please contact:**

#### **IBA**

Marie Gahylle  
Corporate assistant  
Tel: +32 10 47 58 90

[InvestorRelations@iba-group.com](mailto:InvestorRelations@iba-group.com)

#### **For media and investor enquiries:**

#### **Consilium Strategic Communications**

Amber Bielecka, Mary-Jane Elliott, Matthew Neal  
+44 (0) 207 920 2333

[IBA@consilium-comms.com](mailto:IBA@consilium-comms.com)

#### **About IBA**

IBA (Ion Beam Applications S.A.) is a cancer diagnostics and treatment equipment company and the worldwide technology leader in the field of proton therapy.

The Company's primary expertise lies in the development of next generation proton therapy technologies, providing oncology care providers with premium quality services and equipment. IBA's proton therapy solutions are scalable and adaptable, offering universal full scale proton therapy centers as well as next generation compact, single room systems. IBA also focuses on the development and supply of dosimetry solutions for Quality Assurance as well as particle accelerators for medical and industrial applications.

IBA employs more than 1,200 people worldwide and is listed on Euronext Brussels, (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB), more information can be found at: [www.iba-worldwide.com](http://www.iba-worldwide.com)